S-1 in combination with CPT-11 plus trastuzumab for pretreated HER2+metastatic breast cancer

被引：0
|
作者：
Toh, U. [1 ]
Iwakuma, N. [1 ]
Mishima, M. [1 ]
Furukawa, M. [1 ]
Fujii, T. [1 ]
Ogo, E. [2 ]
Nakagawa, S. [3 ]
Tanaka, M. [4 ]
Akagi, Y. [1 ]
机构：
[1] Kurume Univ, Sch Med, Surg, Kurume, Fukuoka 830, Japan
[2] Kurume Univ, Sch Med, Radiol, Kurume, Fukuoka 830, Japan
[3] Natl Hosp Org, Kyushu Med Ctr, Breast Surg, Fukuoka, Japan
[4] Kurume Gen Hosp, Breast Surg, Kurume, Fukuoka, Japan
来源：
BREAST | 2015年 / 24卷
关键词：
D O I：
10.1016/S0960-9776(15)70059-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P008
引用
收藏
页码：S28 / S28
页数：1
相关论文
共 50 条
  • [21] Use and safety of trastuzumab emtansin in HER2+metastatic breast cancer in a tertiary hospital
    Chaguaceda Galisteo, C.
    Manzaneque Gordon, Alba
    Del Rio Torres, Hector Jose
    Baro, Natalia Creus
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2017, 39 (01) : 286 - 286
  • [22] Trastuzumab for HER2+metastatic breast cancer in clinical practice: Cardiotoxicity and overall survival
    Rossi, Marta
    Carioli, Greta
    Bonifazi, Martina
    Zambelli, Alberto
    Franchi, Matteo
    Moja, Lorenzo
    Zambon, Antonella
    Corrao, Giovanni
    La Vecchia, Carlo
    Zocchetti, Carlo
    Negri, Eva
    EUROPEAN JOURNAL OF CANCER, 2016, 52 : 41 - 49
  • [23] Predictors of survival in patients with HER2+metastatic breast cancer (MBC) treated with trastuzumab
    Olson, E. M.
    Najita, J. S.
    Sohl, J.
    Arnaout, A.
    Winer, E. P.
    Lin, N. U.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [24] Phase I/II study of CPT-11 plus S-1 in patients with advanced gastric cancer.
    Komatsu, Y
    Yuuki, S
    Fuse, N
    Takei, M
    Miyagishima, T
    Kudo, M
    Hashino, S
    Asaka, M
    Sakata, Y
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 361S - 361S
  • [25] A phase I study of combination therapy with S-1 and irinotecan (CPT-11) in patients with advanced colorectal cancer
    Manabu Shiozawa
    Nobuhiro Sugano
    Kazuhito Tsuchida
    Soichiro Morinaga
    Makoto Akaike
    Yukio Sugimasa
    Journal of Cancer Research and Clinical Oncology, 2009, 135 : 365 - 370
  • [26] A phase I study of combination therapy with S-1 and irinotecan (CPT-11) in patients with advanced colorectal cancer
    Shiozawa, Manabu
    Sugano, Nobuhiro
    Tsuchida, Kazuhito
    Morinaga, Soichiro
    Akaike, Makoto
    Sugimasa, Yukio
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2009, 135 (03) : 365 - 370
  • [27] COMBINATION TREATMENT OF S-1 WITH CPT-11 TO OVERCOME 5-FLUOROURACIL RESISTANCE IN BLADDER CANCER (JAPAN)
    Ide, H.
    Kikuchi, E.
    Yasumizu, Y.
    Hattori, S.
    Hasegawa, M.
    Miyajima, A.
    Oya, M.
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2011, 41 (03) : I4 - I4
  • [28] Which is more recommendable as the second line chemotherapy to S-1 for advanced gastric cancer; combination of CPT-11 plus CDDP or weekly paclitaxel?
    Imamura, H
    Furukawa, H
    Kishi, K
    Tatsuta, M
    Masutani, S
    Fukunaga, M
    Nakayama, T
    Shimizu, J
    Takemoto, H
    Kishimoto, T
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 347S - 347S
  • [29] THE CHALLENGE OF VALUE-BASED PRICING IN COMBINATION THERAPY:THE CASE OF TRASTUZUMAB AND PERTUZUMAB IN HER2+METASTATIC BREAST CANCER
    Jiao, B.
    Garrison, L. P.
    VALUE IN HEALTH, 2020, 23 : S34 - S35
  • [30] The challenge of value-based pricing in combination therapy: the case of trastuzumab and pertuzumab in HER2+metastatic breast cancer
    Jiao, Boshen
    Garrison, Louis P., Jr.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2021, 21 (03) : 495 - 502
12345